As we’ve said before, and throughout our website, for publicly traded life sciences companies, having at-the-market financing in the toolkit just makes sense. ATMs deliver control over the timing and amount of stock that reaches the market, giving life sciences organizations the flexibility to fund a clinical trial, make leveraged investments, ride the waves of an industry-specific event, and anything else that benefits from access to measured amounts of equity capital over time.
Here’s another benefit: ATM offerings provide the lowest cost of capital, too.
- Deal timeframe: 1/1/2012 – 9/25/2012
- Filter by issuer market cap: $30 million – $7 billion
- Warrants cost calculated using Black Scholes European option pricing model
- Market discount determined by calculating the percent change from the deal price and the stock price one day prior to deal announcement